Search - tctmd.com

Displaying 501 - 520 of 1463

Sort: Relevancy | Date

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

July 23, 2015

News Industry News

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

July 22, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Symic Biomedical Selects Vascular Clinical Candidate

July 20, 2015

Presentation SCCT 2015

Identifying Risk Beyond Stenosis in the ED Lessons Learned from ROMICAT

Presenter: Maros Ferencik

July 18, 2015

News Industry News

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

July 16, 2015

News Daily News

肺栓塞发作后，二级抗凝效果未持续

L.A. McKeown

July 13, 2015

News Industry News

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

Presentation

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Presenter: Francis Couturaud

July 10, 2015

News Daily News

房颤患者过渡治疗无法预防血栓栓塞，且会增加出血

Yael L. Maxwell

July 10, 2015

News Industry News

UK launch for Daiichi's bloodthinner Lixiana

July 10, 2015

News Daily News

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Yael L. Maxwell

July 10, 2015

News Industry News

FDA strengthens warning on NSAID labels

July 10, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Industry News

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

July 09, 2015

News Industry News

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

July 09, 2015

News Daily News

更新后的脑卒中指南支持对特定的患者使用支架拔出器

July 01, 2015

Advertisement

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

Eagle Pharmaceuticals’ RTU Bivalirudin NDA Accepted for Filing

Cardiome Submits Supplemental New Drug Submission (sNDS) For AGGRASTAT To Health Canada

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Symic Biomedical Selects Vascular Clinical Candidate

Identifying Risk Beyond Stenosis in the ED Lessons Learned from ROMICAT

Hospira Announces U.S. Launch of Generic Bivalirudin for Injection

肺栓塞发作后，二级抗凝效果未持续

NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

房颤患者过渡治疗无法预防血栓栓塞，且会增加出血

UK launch for Daiichi's bloodthinner Lixiana

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

FDA strengthens warning on NSAID labels

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)

Regeneron and Sanofi Announce Phase 3 Results Showing LDL-C Reductions of More Than 60 Percent in Japanese Patients Treated with Praluent® (alirocumab) Injection

更新后的脑卒中指南支持对特定的患者使用支架拔出器

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content